Glenmark Life

GLS08 May 2024

Pharmaceuticals

₹

+10.35 (+1.25%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Glenmark Life

Glenmark Life

Pharmaceuticals

GLS08 May 2024

₹

+10.35 (+1.25%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
09-Oct-2023	D	This is to inform you that the Board of Directors ('Board') of the Company has at its meeting held today i.e. October 09, 2023, inter-alia, declared Interim Equity Dividend for the financial year 2023-24 of Rs. 22.50/- per equity share of Rs. 2 each. As intimated vide our letter dated October 04, 2023, the record date for reckoning the list of shareholders who shall be entitled to receive the said interim dividend shall be Tuesday, October 17, 2023. The interim dividend will be paid to such shareholders on or after October 23, 2023.	17-Oct-2023
16-Mar-2023	D	This is to inform you that the Board of Directors ('Board') of the Company has at its meeting held today i.e. March 16, 2023, inter-alia, declared Interim Equity Dividend for the financial year 2022-23 of Rs. 21/- per equity share of Rs. 2 each. As intimated vide our letter dated March 14, 2023, the record date for reckoning the list of shareholders who shall be entitled to receive the said interim dividend shall be Friday, March 24, 2023. The interim dividend will be paid to such shareholders on or after March 29, 2023. The Board meeting commenced at 4:30 p.m. and concluded at 6.05 p.m.	24-Mar-2023
21-Apr-2022	D	Glenmark Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 20, 2022, inter alia, has recommended final Dividend of Rs. 10.50 per share (face value of Rs. 2/- each) on the Equity Share Capital of the Company for the financial year 2021 - 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting.	15-Sep-2022
10-Nov-2021	D	Glenmark Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 11, 2021, inter alia, has declared an interim dividend of Rs. 10.5/- per equity share of face value of Rs. 2/- each for the financial year ending March 31, 2022.	22-Nov-2021
03-May-2024	BC	Please find enclosed herewith Notice of Postal Ballot.	03-Jun-2024
18-Apr-2024	BC	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2024 inter alia to consider and approve Audited Financial Results of the Com	25-Apr-2024
25-Apr-2024	BC	Appointment of Dr. Savan Godiawala (DIN: 07874111) as an Additional Director - Non-Executive - Independent.	25-Apr-2024
22-Apr-2024	BC	Please find enclosed herewith Intimation of Resignation of Ms. Gita Nayyar (DIN:07128438) as a non-executive, Independent Director.	22-Apr-2024
09-Oct-2023	BC	This is to inform you that the Board of Directors ('Board') of the Company has at its meeting held today i.e. October 09, 2023, inter-alia, declared Interim Equity Dividend for the financial year 202	31-Mar-2024

No Rights has been declared by GLS

Book Closure

Record Date	Split Date	Purpose
03-Jun-2024	01 Jan'1900	Please find enclosed herewith Notice of Postal Ballot.
25-Apr-2024	-	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2024 inter alia to consider and approve Audited Financial Results of the Com
25-Apr-2024	-	Appointment of Dr. Savan Godiawala (DIN: 07874111) as an Additional Director - Non-Executive - Independent.
22-Apr-2024	-	Please find enclosed herewith Intimation of Resignation of Ms. Gita Nayyar (DIN:07128438) as a non-executive, Independent Director.
31-Mar-2024	-	This is to inform you that the Board of Directors ('Board') of the Company has at its meeting held today i.e. October 09, 2023, inter-alia, declared Interim Equity Dividend for the financial year 202

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Glenmark Life Sciences Ltd ₹840.65(+10.35/1.25%)	840.65	+10.35	10,300.25	53.46	21.87	4.42
Astrazeneca Pharma India Ltd ₹5,311.15(+104.05/2.00%)	5,311.15	+104.05	13,277.88	63.02	83.25	20.27
Cipla Ltd ₹1,384.80(-3.10/-0.22%)	1,384.80	-3.10	111,808.06	48.80	34.00	4.32
Bliss GVS Pharma Ltd ₹112.00(-0.45/-0.40%)	112.00	-0.45	1,172.54	47.96	15.47	1.19
Amrutanjan Health Care Ltd ₹772.10(+24.75/3.31%)	772.10	+24.75	2,232.19	26.41	50.73	8.52
Abbott India Ltd ₹25,945.60(+229.35/0.89%)	25,945.60	+229.35	55,134.40	14.35	48.13	17.73

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Gross Sales	536.60	572.80	595.36	578.45	621.32	540.73
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	536.60	572.80	595.36	578.45	621.32	540.73
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	3.13	1.69	5.37	1.85	2.84	6.61
Total Income	539.73	574.50	600.73	580.30	624.16	547.34
Total Expenditure	395.15	400.25	428.28	385.29	414.89	395.28
PBIDT	144.58	174.25	172.45	195.01	209.27	152.06
Interest	0.36	0.39	0.40	0.40	0.12	0.16
PBDT	144.21	173.86	172.05	194.62	209.15	151.90
Depreciation	14.53	13.18	13.13	12.61	11.52	10.76
Tax	31.05	38.86	38.70	43.60	47.31	33.18
Deferred Tax	0.69	3.06	1.49	2.96	3.96	2.97
Reported Profit After Tax	97.94	118.77	118.74	135.45	146.36	104.99
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	97.94	118.77	118.74	135.45	146.36	104.99

EPS (Unit Curr.)	7.99	9.69	9.69	11.05	11.94	8.57
EPS (Adj) (Unit Curr.)	7.99	9.69	9.69	11.05	11.94	8.57
Calculated EPS (Unit Curr.)	7.99	9.69	9.69	11.05	11.95	8.57
Calculated EPS (Adj) (Unit Curr.)	7.99	9.69	9.69	11.05	11.95	8.57
Calculated EPS (Ann.) (Unit Curr.)	31.97	38.77	38.76	44.22	47.78	34.28
Calculated EPS (Adj) (Ann.) (Unit Curr.)	31.97	38.77	38.76	44.22	47.78	34.28
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	1125.00	0.00	0.00	0.00
Equity	24.51	24.51	24.51	24.51	24.51	24.51
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	2.00	2.00	2.00	2.00	2.00	2.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	26.94	30.42	28.97	33.71	33.68	28.12
PBDTM(%)	26.87	30.35	28.90	33.65	33.66	28.09
PATM(%)	18.25	20.73	19.94	23.42	23.56	19.42

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	24.51	24.51	1.96	1.96	1.96	0.01
Reserves Total	2113.70	2029.81	750.79	399.73	86.17	-1.41
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	2138.21	2054.32	752.75	401.69	88.13	-1.40
Secured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	19.36	2.88	0.00	0.02	0.02	0.00
Total Debt	19.36	2.88	0.00	0.02	0.02	0.00
Total Liabilities	2157.57	2057.20	752.75	401.71	88.15	-1.40
APPLICATION OF FUNDS :
Gross Block	936.48	705.53	651.90	594.82	475.57	0.00
Less : Accumulated Depreciation	155.85	115.77	79.10	48.58	19.26	0.00
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	780.63	589.76	572.80	546.24	456.31	0.00
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	61.62	96.96	14.10	10.73	80.39	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.08	0.08	0.08	0.08	0.08	0.00
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	604.17	516.24	513.42	412.78	400.84	0.04
Sundry Debtors	806.77	673.49	619.50	638.63	448.09	0.03
Cash and Bank	309.40	512.16	115.60	10.00	2.06	0.01
Loans and Advances	130.01	62.69	150.52	98.71	79.70	0.01
Total Current Assets	1850.34	1764.59	1399.04	1160.12	930.69	0.08
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	479.53	355.88	1187.85	1285.10	1364.00	1.47
Provisions	22.62	26.44	33.60	22.34	16.40	0.01
Total Current Liabilities	502.15	382.32	1221.44	1307.44	1380.39	1.48
Net Current Assets	1348.20	1382.27	177.59	-147.33	-449.70	-1.40
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.81	1.07	2.03	0.13	2.29	0.00
Deferred Tax Liability	44.25	32.57	24.91	16.58	9.14	0.00
Net Deferred Tax	-42.44	-31.50	-22.88	-16.45	-6.85	0.00
Total Assets	2148.09	2037.57	741.69	393.28	80.23	-1.40
Contingent Liabilities	2.22	2.22	2.22	2.22	2.76	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	512.16	115.60	10.00	2.06	0.01
Net Cash from Operating Activities	313.40	597.59	388.11	195.01	10.35
Net Cash Used In Investing Activities	-154.15	-122.23	-68.73	-50.52	-8.83
Net Cash Used In Financing Activities	-387.59	-78.80	-213.78	-136.55	0.54
Net Inc./Dec In Cash And Cash Equivalents	-228.33	396.56	105.60	7.94	2.05
Cash And Cash Equivalents At End Of The Year	283.82	512.16	115.60	10.00	2.06

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

82.85%

FII Shareholding

5.01%

DII Shareholding

1.40%

Public Shareholding

10.73%

**Promoter pledged shareholding 82.85%

About Glenmark Life Sciences Ltd

Glenmark Life Sciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 10300.25 crores. It has reported a sales of Rs. 536.6 crores and a net profit of Rs. 97.94 crores for the quarter ended December 2018. The company management includes Glenn Saldanha, Glenn Saldanha,V S Mani,Yasir Yusufali Rawjee,Vinod Naik,Sridhar Gorthi,Manju Agarwal,Taruvai Laxminarayanan Easwar,Gita Nayyar (Glenmark Life Sciences Ltd) among others.

Chairman

Glenn Saldanha

Registered office

Plot No. 170-172 Chandramouli,Industrial Est.Mohol Bazarpeth,Solapur,Maharashtra,413213

FAX :

Background

Incorporation Year2011

Face Value₹2

Market Lot1

How to buy Glenmark Life shares on nse?

To buy Glenmark Life shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Glenmark Life share price today?

The Glenmark Life shares price on nse is Rs.840.65 today.

What is the market cap of Glenmark Life shares on BSE ?

The company has a market capitalization of Rs.10300.25Cr

What is the PE & PB ratio of Glenmark Life shares ?

PE is 21.87 and PB is 4.42

What is the 52 Week High and Low of Glenmark Life shares?

Glenmark Life stock price high: Rs.904.2 Glenmark Life stock price low: Rs.512.7